GlaxoSmithKline Consumer Nigeria (NSA:GLAXOSMITH) Net Income From Continuing Operations : ₦606 Mil (TTM As of Jun. 2023)

View and export this data going back to 2001. Start your Free Trial

What is GlaxoSmithKline Consumer Nigeria Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. GlaxoSmithKline Consumer Nigeria's net income from continuing operations for the three months ended in Jun. 2023 was ₦185 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Jun. 2023 was ₦606 Mil.

GlaxoSmithKline Consumer Nigeria Net Income From Continuing Operations Historical Data

The historical data trend for GlaxoSmithKline Consumer Nigeria's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlaxoSmithKline Consumer Nigeria Net Income From Continuing Operations Chart

GlaxoSmithKline Consumer Nigeria Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Net Income From Continuing Operations

Get a 7-Day Free Trial

617.62

917.10

622.23

658.81

771.15

GlaxoSmithKline Consumer Nigeria Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23
Net Income From Continuing Operations	Get a 7-Day Free Trial															194.37	154.98	134.19	287.61	184.55

GlaxoSmithKline Consumer Nigeria Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₦606 Mil.

GlaxoSmithKline Consumer Nigeria (NSA:GLAXOSMITH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GlaxoSmithKline Consumer Nigeria PLC (NSA:GLAXOSMITH) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 1, Industrial Avenue, Ilupeju, P.M.B. 21218, Ikeja, GSK House, Lagos, NGA

Website

https://www.ng.gsk.com

GlaxoSmithKline Consumer Nigeria PLC is a healthcare company that researches, develops, and manufactures pharmaceutical medicines, vaccines, and consumer healthcare products. The company has two reportable segments, the Consumer Healthcare segment consisting of oral care, over-the-counter (OTC) medicines, and nutritional healthcare; and the Pharmaceuticals segment consisting of vaccines and prescription drugs. The company's product line includes panadol, Andrews liver salt, Macleans, ampiclox, Sensodyne, and others. The generates maximum revenue from the Pharmaceuticals segment.

GlaxoSmithKline Consumer Nigeria (NSA:GLAXOSMITH) Headlines

No Headlines